EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Naturally Occurring Deletions/Insertions in HBV Core Promoter Tend to Decrease in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients during Antiviral Therapy

Yaqin Peng, Baoming Liu, Jinlin Hou, Jian Sun, Ran Hao, Kuanhui Xiang, Ling Yan, Jiangbo Zhang, Hui Zhuang, Tong Li

Antiviral Therapy · 2015-08 · 20 (6) · 623-632

DOI: 10.3851/imp2955 ↗
AstrattDettalji biblijografiċi

Astratt

Background Mutations in HBV core promoter (CP) are suggested to affect viral replication and disease progression. We investigated CP deletion/insertion mutations (Del/Ins) in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients before and during antiviral treatment. Methods Direct and clone sequencings were used for detection of CP Del/Ins in 12 patients. The dynamic changes of CP Del/Ins were tracked in these cases until week 48 of treatment. The effects of Del/Ins on CP activities and hepatitis B X protein (HBx) were analysed using luciferase assay and sequence comparison, respectively. Furthermore, 292 untreated HBeAg-positive CHB cases were also analysed. Results Twelve cases with multi-peak PCR direct sequencing electropherograms at baseline were con-firmed to have CP Del/Ins by clone sequencing, with detection rates varying from 14.8% to 93.3% of clones analysed. Follow-up studies showed the detection rates of CP Del/Ins in patients decreased from 100% (12/12) at baseline to 16.7% (2/12) at week 48 of treatment ( P

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →